ArticleFEBS letters2026
Identification of a Shiga toxin A-derived peptide internalized into Gb3 receptor-bearing cells via interaction with the Shiga toxin B subunit.
Article in FEBS letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Here, we explored the potential of peptides derived from the catalytic A subunit of Shiga toxin (STxA) to be drug carriers. Using time-resolved biosensor-based assays we examined the interaction between a variety of STxA peptides (varying in length and end groups) and the cell receptor binding subunit (STxB). Peptides which bound STxB included the C-terminal α-helix protruding into the interior of STxB and the ß-strands binding to its surface. Specifically, the C-terminal 26-mer resulted in a stable complex in a physiologically relevant pH range for drug delivery. Real-time cell-binding analysis showed that the peptide-STxB complex binds to and is internalized by Gb3-overexpressing cancer cell lines with surface-exposed Gb3 receptors. It highlights STxA-derived peptides as potential as drug carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.